个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

Efficacy and safety of pemetrexed/cisplatin versus gemcitabine/cisplatin as first-line treatment in Chinese patients with advanced nonsquamous non-small cell lung cancer.

| 认领 | 导出 | |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ SCIE

作者：
Wu Yi-Long[1,*1] * ; Lu Shun[2] ; Cheng Ying[3] ; Zhou Caicun[4] ; Wang Mengzhao[5] ; Qin Shukui[6] ; Lu You[7] ; Zhang Yang[8] ; Zhu Yunzhong[9] ; Song Xiangqun[10] ; Wang Xin[11] ; Barraclough Helen[12] ; Zhang Xiaoqing[13] ; Chi Haidong[13] ; Orlando Mauro[14] ;
机构： [1]Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangdong, China [2]Lung Cancer Center, Shanghai Chest Hospital, affiliated to Shanghai JiaoTong University, Shanghai, China [3]Department of Oncology, Cancer Hospital of Jilin Province, Changchun, China [4]Department of Oncology, Shanghai Pulmonary Hospital, School of Medicine Tongji University Affiliated Cancer Institute, Shanghai, China [5]Department of Oncology, Peking Union Medical College Hospital, Beijing, China [6]Department of Oncology, 81st Hospital of the Chinese PLA, Nanjing, China [7]Department of Oncology, West China School of Medicine, West China Hospital, Sichuan University, Chengdu, China [8]Department of Oncology, the Second Hospital of Dalian Medical University, Dalian, China [9]Department of Chest Tumor, Beijing Chest Hospital, affiliated to Capital Medical University, Beijing, China [10]Cancer Hospital affiliated to Guangxi Medical University, Nanning, China [11]Asia Pacific Statistical Sciences, Lilly China Drug Development and Medical Affairs Center, Shanghai, China [12]Asia Pacific Statistical Sciences, Eli Lilly Australia, Sydney, Australia [13]Oncology, Lilly China Drug Development and Medical Affairs Center, Shanghai, China [14]Oncology Emerging Markets, Eli Lilly Interamérica Inc., Buenos Aires, Argentina
出处：
DOI： 10.1016/j.lungcan.2014.07.007
ISSN：

关键词： Cisplatin Chinese First-line chemotherapy Gemcitabine Non-small cell lung cancer Nonsquamous Pemetrexeda

摘要：
Retrospective subgroup analysis in JMDB study indicates that the between-arm differences in overall survival (OS) in the East Asian subgroup were consistent with those observed in the entire JMDB study population. This bridging study (JMIL) further evaluated the efficacy and safety of first-line pemetrexed/cisplatin (PC) versus gemcitabine/cisplatin (GC) in Chinese patients with nonsquamous non-small cell lung cancer (NSCLC). The primary endpoint of this local registration trial was designed to compare OS in the combined dataset, consisting of Chinese patients in JMIL and 1252 nonsquamous patients in JMDB. Chinese patients with stage IIIB/IV nonsquamous NSCLC were randomly assigned (1:1) to 6 cycles maximum (21 days/cycle) of pemetrexed 500mg/m(2)+cisplatin 75mg/m(2) (day 1), or gemcitabine 1250mg/m(2) (days 1 and 8)+cisplatin 75mg/m(2) (day 1). In JMIL, 256 Chinese patients were randomized (PC, n=126; GC, n=130). Patient baseline characteristics were balanced between treatment arms. In the combined dataset, PC was superior to GC in prolonging OS, with adjusted hazard ratio (HR) of 0.87 (95% CI: 0.77-0.98, p=0.023) and median OS of 11.76 versus 10.94 months. In the JMIL-only population, no significant OS difference observed between treatment arms (adjusted HR=1.03 [95% CI: 0.77-1.39, p=0.822]; unadjusted HR=0.996 [95% CI: 0.74-1.33, p=0.980]), nor for other secondary efficacy endpoints. Significantly fewer patients in the PC arm experienced drug-related grade 3/4 toxicities, 54 (43.2%) versus 71 (55.9%) for GC (p=0.045), with significantly lower rates of leukocytopenia, thrombocytopenia, and fatigue. This study showed that in the combined population, OS of PC was superior to GC, while in the Chinese-only population, no significant difference was observed; a better safety and risk/benefit profile was found in the PC arm. A PC regimen should be considered as a standard of care in Chinese nonsquamous NSCLC patients in a first-line setting. Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

语种：
外文
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2014]版：
大类 | 2 区 医学
小类 | 2 区 呼吸系统 3 区 肿瘤学
最新[2023]版：
大类 | 2 区 医学
小类 | 3 区 肿瘤学 3 区 呼吸系统
JCR分区：
出版当年[2014]版：
Q1 RESPIRATORY SYSTEM Q2 ONCOLOGY
最新[2023]版：
Q1 RESPIRATORY SYSTEM Q1 ONCOLOGY

影响因子： 最新[2023版] 最新五年平均 出版当年[2014版] 出版当年五年平均 出版前一年[2013版] 出版后一年[2015版]

第一作者：
第一作者机构： [1]Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangdong, China [*1]Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangdong, China
通讯作者：
通讯机构： [1]Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangdong, China [*1]Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangdong, China
推荐引用方式(GB/T 7714)：
Wu Yi-Long,Lu Shun,Cheng Ying,et al.Efficacy and safety of pemetrexed/cisplatin versus gemcitabine/cisplatin as first-line treatment in Chinese patients with advanced nonsquamous non-small cell lung cancer.[J].LUNG CANCER.2014,85(3):401-407.doi:10.1016/j.lungcan.2014.07.007.
APA：
Wu Yi-Long,Lu Shun,Cheng Ying,Zhou Caicun,Wang Mengzhao...&Orlando Mauro.(2014).Efficacy and safety of pemetrexed/cisplatin versus gemcitabine/cisplatin as first-line treatment in Chinese patients with advanced nonsquamous non-small cell lung cancer..LUNG CANCER,85,(3)
MLA：
Wu Yi-Long,et al."Efficacy and safety of pemetrexed/cisplatin versus gemcitabine/cisplatin as first-line treatment in Chinese patients with advanced nonsquamous non-small cell lung cancer.".LUNG CANCER 85..3(2014):401-407

相关文献

[1]Cisplatin and Gemcitabine With or Without Bevacizumab in EGFR Wild-type Non-Small Cell Lung Cancer [2]A randomized phase II study of recombinant human endostatin plus gemcitabine/cisplatin compared with gemcitabine/cisplatin alone as first-line therapy in advanced non-small-cell lung cancer [3]吉西他滨联合顺铂或卡铂治疗晚期非小细胞肺癌的近期疗效 [4]Factors associated with gene aberration test status and treatment decision in patients with unresectable Stage IIIB/IV nonsquamous non-small cell lung cancer: A multicenter survey in China (CTONG 1506) [5]A multicenter survey of first-line treatment patterns and gene aberration test status of patients with unresectable Stage IIIB/IV nonsquamous non-small cell lung cancer in China (CTONG 1506) [6]Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation- positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial [7]Utilization of circulating cell-free DNA profiling to guide first-line chemotherapy in advanced lung squamous cell carcinoma(Open Access) [8]Gefitinib Plus Chemotherapy Versus Chemotherapy in Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer Resistant to First-Line Gefitinib (IMPRESS): Overall Survival and Biomarker Analyses. [9]吉吉西他滨/卡铂和吉西他滨/顺铂方案治疗晚期非小细胞肺癌的疗效比较 [10]A multicenter survey of first-line treatment patterns and gene aberration test status of patients with unresectable Stage IIIB/IV nonsquamous non-small cell lung cancer in China (CTONG 1506)

资源点击量：53080 今日访问量：0 总访问量：4588 更新日期：2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持：重庆聚合科技有限公司 地址：成都市人民南路四段55号